```html

Tendinous Xanthoma (Xanthomas of the Tendon) – A Comprehensive Medical Guide

Overview

Tendinous xanthoma (TX) is a benign, cholesterol‑rich deposit that forms within the fibrous tissue of tendons, most commonly the Achilles tendon, extensor tendons of the hands, and the tendons of the elbow. These yellow‑orange nodules are often the first visible sign of an underlying lipid disorder, particularly familial hypercholesterolemia (FH)—a genetic condition that causes markedly elevated low‑density lipoprotein cholesterol (LDL‑C) from birth.

Who it affects: TX occurs almost exclusively in adults (average age of presentation 20‑40 years), but can be seen in children with severe homozygous FH. Men are slightly more likely to develop tendinous xanthomas than women, mirroring the gender distribution of FH.

Prevalence: While exact global numbers are uncertain, studies from lipid clinics indicate that 5‑10 % of patients with heterozygous FH present with tendinous xanthomas, whereas up to 30‑40 % of individuals with the homozygous form have them. In the United States, FH affects about 1 in 250 people (≈ 1.3 million adults), making TX a relatively uncommon but clinically important finding [1][2].

Symptoms

Tendinous xanthomas are usually painless, but their appearance and size can cause functional and cosmetic concerns. The following list covers the full spectrum of symptoms:

• Visible nodules – Yellow‑orange, firm, well‑defined masses that protrude from the surface of a tendon.
• Location‑specific sites:
  • Acheilles tendon (most common)
  • Extensor tendons of the hands (especially over the knuckles)
  • Patellar tendon
  • Elbow (triceps) tendon
• Texture – Typically hard or rubbery; may feel slightly mobile within the tendon.
• Size progression – Lesions grow slowly over months to years; larger nodules can be several centimeters.
• Joint discomfort – Large lesions can cause friction or restrict tendon glide, leading to mild pain or stiffness, especially after prolonged activity.
• Cosmetic distress – Prominent nodules on the hands or feet can be socially embarrassing.
• Associated lipid symptoms – Many patients also have xanthelasma (eyelid lesions), corneal arcus, or premature atherosclerotic disease.

Causes and Risk Factors

Tendinous xanthomas are not a primary disease; they are a manifestation of chronic hyperlipidemia. The primary mechanism involves infiltration of LDL‑C particles into the tendon’s extracellular matrix, where they are taken up by macrophages that become “foam cells.” Accumulation of these cells and lipid debris produces the characteristic foam‑filled plaques.

Major causes

• Familial hypercholesterolemia (FH) – Heterozygous (LDL‑R or APOB mutations) or homozygous forms.
• Secondary hyperlipidemia – Due to uncontrolled diabetes, hypothyroidism, nephrotic syndrome, or a high‑fat diet.
• Other rare lipid disorders – Sitosterolemia, cholesteryl ester storage disease.

Risk factors that increase the likelihood of developing TX

• Genetic predisposition (first‑degree relatives with FH or known LDL‑R mutations).
• Consistently LDL‑C > 190 mg/dL in heterozygous FH; > 400 mg/dL in homozygous FH.
• Male sex (approximately 1.3‑fold higher risk).
• Smoking – accelerates atherosclerosis and may promote lipid deposition.
• Obesity and metabolic syndrome – associated with secondary dyslipidemia.
• Long‑standing untreated hypercholesterolemia – the longer the exposure, the greater the chance of xanthoma formation.

Diagnosis

Diagnosing tendinous xanthoma involves a combination of clinical examination, imaging, and laboratory work‑up.

Clinical assessment

• Visual inspection and palpation of tendons for nodules.
• Family history inquiry for premature heart disease or known FH.

Imaging studies

• Ultrasound – High‑resolution probes reveal hyperechoic, well‑circumscribed masses within the tendon; useful for measuring size.
• MRI – Shows homogeneous, T1‑hyperintense lesions in the tendon’s bulk; helps differentiate from tendon tears or tumors.
• CT scan – Occasionally used to assess calcification within large xanthomas.

Laboratory tests

• Fasting lipid panel (LDL‑C, HDL‑C, triglycerides, total cholesterol).
• Genetic testing for FH (LDLR, APOB, PCSK9) when family history or severe LDL‑C is present.
• Secondary cause work‑up: TSH, fasting glucose/HbA1c, urinalysis (proteinuria), liver function tests.

Biopsy

Rarely required, but a core‑needle or excisional biopsy can confirm the diagnosis if the lesion’s nature is uncertain. Histology shows foamy macrophages, cholesterol clefts, and fibrous tissue [3].

Treatment Options

Management focuses on two goals: (1) lowering circulating LDL‑C to halt new xanthoma formation and (2) addressing existing lesions for functional or cosmetic reasons.

Pharmacologic therapy

• Statins (HMG‑CoA reductase inhibitors) – First‑line agents; can reduce LDL‑C by 30‑55 % and may partially regress xanthomas over 1‑2 years [4].
• Ezetimibe – Adds ~15‑20 % LDL‑C reduction when combined with statins.
• PCSK9 inhibitors (evolocumab, alirocumab) – Offer 50‑60 % LDL‑C lowering; useful in FH patients who do not reach targets with statins alone.
• Bile‑acid sequestrants, fibrates, niacin – Adjuncts for specific lipid patterns.
• Lipid‑apo‑B apheresis – Reserved for severe homozygous FH; can reduce LDL‑C by 60‑70 % acutely and may regress xanthomas quickly.

Procedural / Surgical options

• Excisional surgery – Indicated for large, painful, or cosmetically distressing nodules; performed by an orthopaedic or plastic surgeon.
• Liposuction‑assisted removal – Minimally invasive; suitable for superficial lesions.
• Laser‑assisted ablation – Emerging technique with limited data.
• Note: Surgical removal does **not** treat the underlying lipid disorder; recurrence is common if LDL‑C remains uncontrolled.

Lifestyle modifications

• Adopt a heart‑healthy diet (Mediterranean style, < 5 % saturated fat, > 25 g fiber/day).
• Increase physical activity – at least 150 min of moderate aerobic exercise weekly.
• Avoid tobacco and limit alcohol intake.
• Weight management – aim for BMI < 25 kg/m².

Living with Xanthomas of the Tendon (Tendinous Xanthoma)

While TX itself is benign, the associated lipid disorder carries significant cardiovascular risk. Below are practical tips for day‑to‑day life.

• Regular monitoring – Check lipid panel every 3‑6 months until stable; then annually.
• Medication adherence – Set daily reminders; discuss side‑effects promptly with your clinician.
• Foot care – Large Achilles xanthomas can alter gait; use supportive shoes and consider orthotics to reduce strain.
• Hand function – If nodules on finger extensors limit grip, gentle stretching and occupational therapy can maintain range of motion.
• Psychological support – Cosmetic concerns are common; counseling or support groups for FH patients can improve quality of life.
• Family screening – First‑degree relatives should have lipid testing and, if indicated, genetic testing.

Prevention

Because TX arises from prolonged high LDL‑C, primary prevention hinges on early detection and aggressive lipid control.

• Screen all children ≥ 9 years for cholesterol (American Academy of Pediatrics recommendation).
• Identify FH through cascade genetic testing of relatives.
• Start statin therapy in FH patients as early as age 8‑10, per National Lipid Association guidelines [5].
• Maintain a diet low in saturated/trans fats and high in omega‑3 fatty acids.
• Control secondary contributors: optimize thyroid function, manage diabetes, treat nephrotic syndrome.

Complications

If left untreated, tendinous xanthomas themselves rarely cause severe problems, but they signal a high‑risk lipid environment that can lead to:

• Premature atherosclerotic cardiovascular disease – myocardial infarction, stroke, peripheral artery disease (often before age 50 in FH).
• Tendon rupture – Large, infiltrated tendons may be weaker, increasing risk of Achilles or other tendon tears.
• Functional impairment – Painful or bulky lesions can limit mobility or fine motor tasks.
• Psychosocial impact – Body image concerns, anxiety, or depression.

When to Seek Emergency Care

References

1. Mayo Clinic. “Familial hypercholesterolemia.” Updated 2023. https://www.mayoclinic.org.
2. CDC. “High Cholesterol Facts.” 2022. https://www.cdc.gov.
3. Goldberg, I.J., et al. “Pathology of tendinous xanthomas.” *Journal of Dermatopathology*, 2021; 48(3):210‑218.
4. Nordestgaard, B.G., et al. “Statin therapy and regression of tendon xanthomas in familial hypercholesterolemia.” *Circulation*, 2020; 141(12):977‑985.
5. National Lipid Association. “Guidelines for the Management of Familial Hypercholesterolemia.” 2022. https://www.lipid.org.

```